The NeXT Dx Test is a laboratory developed test performed at Personalis’ CAP-accredited and CLIA’88- certified laboratory. It is intended for profiling a solid tumor’s genomic and molecular characteristics using clinical-grade, next-generation sequencing (NGS) technology to report small nucleotide variants (SNVs), small insertions and deletions (indels), copy number alterations (CNAs), and fusions in up to 247 cancer related genes. Additionally, MSI and exome-wide “true” TMB is reported by leveraging the exome-wide analysis of non-synonymous small variants (SNVs and indels both).